Ipsen is set to purchase all issued and outstanding shares of the French biotech company ImCheck Therapeutics.

A report by GlobalData revealed that the biotech industry witnessed a 70.9% increase in total venture financing deal value.

Remote monitoring technologies offer a vital option for people with diabetes to manage their conditions, with tech developed ...

Roche’s CEO Thomas Schinecker said the drugmaker is continuing talks with the US government over drug pricing reforms, as ...

Early-stage equity raises for biotechs surged by 71% in Q3 2025, hinting that the funding freeze that has gripped the ...

Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn. The ...

Immunotherapy drugs continue to gain momentum across a growing range of disease areas with blockbusters such as Merck’s ...

ICH gives CGT developers a regulatory framework that finally matches the speed and flexibility their groundbreaking therapies ...

HPAPI manufacturing requires the highest safety and containment standards. With geopolitical tensions threatening critical ...

The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing ...

These Phase III results could enhance uptake of Eli Lilly's Verzenio alongside ET in the adjuvant breast cancer setting, if ...

Nearly two dozen antibody drug conjugates (ADCs) have now been approved worldwide and revenues were already well into the ...